Topical Formulations with Nanomicelles for Ocular Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmic formulations lack stability at high temperatures and effective ocular tissue distribution, particularly for anterior and posterior eye delivery, and often include pharmaceutically active agents that have not received regulatory approval for ocular conditions.
Innovation Solution
Development of topical formulations incorporating polyoxyl lipids or fatty acids, such as HCO-40, HCO-60, and HCO-80, and polyalkoxylated alcohols like octoxynol-40, which form nanomicelles, providing stability and improved ocular tissue distribution without the need for approved active agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If current ophthalmic formulations are used, then ocular tissue distribution can be achieved, but stability at high temperatures deteriorates
Solution Approach 1:
The patent changes the physical-chemical parameters of the formulation by incorporating nanomicelles with specific polyoxyl lipids (HCO-40, HCO-60, HCO-80) and fatty acids. These parameter changes in molecular structure and aggregation state enable the formulation to maintain stability at high temperatures while improving ocular tissue distribution.
Solution Approach 2:
The patent creates a composite nanomicellar system combining multiple components: polyoxyl lipids, fatty acids, and surfactants. This composite structure leverages the synergistic properties of each component to achieve both high temperature stability and effective ocular tissue distribution, resolving the technical contradiction between stability and temperature resistance.
2Reliability
If nanomicelles are incorporated to improve ocular tissue distribution, then delivery effectiveness improves, but formulation complexity increases
Solution Approach 1:
The patent segments the formulation into distinct functional components: nanomicelles for targeted delivery, polyoxyl lipids for stability, and surfactants for solubility. This segmentation allows each component to perform its specific function efficiently, improving ocular tissue distribution while managing overall formulation complexity through modular design.
3Object-affected harmful factors
If approved active agents are excluded from the formulation, then safety profile improves, but therapeutic efficacy may be limited
Solution Approach 1:
The patent uses nanomicelles as intermediary carriers that can deliver therapeutic agents to ocular tissues without requiring the active agent itself to be in the formulation. This intermediary approach improves the safety profile by excluding approved active agents while maintaining potential therapeutic efficacy through the delivery capability of the nanomicellar system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations demonstrate enhanced stability at high temperatures and improved ocular tissue distribution, making them suitable for anterior and posterior eye delivery without the inclusion of pharmaceutically active agents that have received regulatory approval for ocular conditions.
Implementation Method 1
the formulations include nanomicelles
Implementation Method 2
a polyoxyl lipid or fatty acid and a polyalkoxylated alcohol
Data Source
AI summary
Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.